Home
Search
SurgiMabSurgiMab
  • Tumor detection
  • Clinical development
  • Company
    • Team
    • Partners
    • Investors
  • News & Events
  • Contact us
  • Français
SurgiMab will attend the World Molecular Imaging Congress 2016 in New York, september 7-10.
  • Tumor detection
  • Clinical development
  • Company
    • Team
    • Partners
    • Investors
  • News & Events
  • Contact us
  • Français
EnglishEnglishFrançaisFrançais

SurgiMab will attend the World Molecular Imaging Congress 2016 in New York, september 7-10.

SurgiMab > News & Events > News > SurgiMab will attend the World Molecular Imaging Congress 2016 in New York, september 7-10.
19 July 2016 Administrateur SurgiMab0

SurgiMab will attend WMIC 2016 : Bérénice Framery, in charge of the company’s internal R&D programs, will be present in New York.

You can meet her in particular during the “Optical Surgical Navigation” session on Wednesday, September 7, 2016, from 9:00 to 15:30, Room 1E10, Javits Convention Center, New York.

World Molecular Imaging Congress - Discover. Visualize. Learn. Cure.

Previous Post
SurgiMab will participate to the BIO International convention 6-9 June 2016
Next Post
SurgiMab announces SGM-101 publication in Surgical Oncology

Recent Posts

  • SurgiMab co-sponsors the Molecular-Guided Surgery meeting that will take place during the SPIE Photonics West conference in San Francisco on Jan 22-23, 2022.
  • SurgiMab will attend the 7th Annual International Congress for Fluorescence-Guided Surgery – Coral Gables, FL, 15th and 16th feb. 2020.
  • SurgiMab sponsors the conference “Molecular-Guided Surgery” of the SPIE Photonics West meeting – San Francisco, 1st and 2nd feb. 2020.
  • SurgiMab announces recruitment of first US patient in pivotal Phase 3 clinical trial evaluating SGM-101 in colorectal cancer patients
  • SurgiMab advances SGM-101 into pivotal Phase 3 clinical trial to improve surgical outcomes in colorectal cancer patients
SurgiMab
Tumor detection Clinical development Company News & Events Contact

About SurgiMab

SurgiMAb develops injectable fluorescent conjugates to be used during Fluorescence-Guided Surgery (FGS) by oncology surgeons so they can clearly delineate tumors and visualize infra-clinical size nodules invisible to their naked eyes.

Latest news

  • SurgiMab co-sponsors the Molecular-Guided Surgery meeting that will take place during the SPIE Photonics West conference in San Francisco on Jan 22-23, 2022.
  • SurgiMab will attend the 7th Annual International Congress for Fluorescence-Guided Surgery – Coral Gables, FL, 15th and 16th feb. 2020.
Home . Legal & credits
Copyright © 2023 SurgiMab. Website by B-to-B Design